Floatz logo

OLESOXIME, E-

Relapsing Remitting Multiple Sclerosis

Hoffmann-La RocheSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the Relapsing Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
Ocrevus
Biocad
Phase 4BBB

View all 50 →

Same molecule, other indications

OLESOXIME, E- is also rated in:

spinal muscular atrophy, type IIDormant
B
Indicative ·
57 / 100
View asset →
spinal muscular atrophy, type IIIDormant
B
Indicative ·
57 / 100
View asset →
spinal muscular atrophyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →